TheraCryf has announced the successful manufacture of the 10kg quantity of its Ox-1 compound, sufficient to complete the critical 28-day regulatory toxicology studies in animals. These studies are expected to commence in 1Q26/2Q26 following the completion of dosing studies which are currently underway to identify the Maximum Tolerated Dose and Dose Range Finding Studies of the compound. TheraCryf is on track to complete all animal studies in 3Q26 and be ready to commence clinical trials in humans by the end of 2026, a key value inflection point for which the company is fully funded. TheraCryf's valuation remains nugatory in relation to pharma deals for Central Nervous System compounds which typically attract upfront payments c5x TheraCryf's current market capitalisation for pre-clinical assets rising to c9x at clinical readiness.
